BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy rating on Novavax Inc. (NASDAQ:NVAX) with a $19 price target.

BTIG analyst Thomas Shrader told investors following the company’s announcement of the results of the initial cohort of its COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial that the primary goal was to exhibit that the immunogenicity of both the COVID-19 and Influenza vaccines was within the protective range with  “interference” not being a strong factor.

He stated that the first CIC data “looks unremarkable – exactly what we hoped for,” adding that the “most positive signs from today’s data” were stronger immunogenicity for the Novavax flu vaccine for some antigens compared to the “gold-standard” flu vaccine FLUZONE-HD.

Novavax Inc. (NASDAQ:NVAX) is a biotechnology company that discovers, develops, and commercializes recombinant vaccines.

While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.